One treatment approach involves the boosting of the host’s suppressive ability against cancer cells as demonstrated by immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death -1 (PD-1; pembrolizumab) and PD ligand-1 (PD-L1; atezolizumab) [16]. The gene discussed is CTLA4; the disease is cancer.